Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567195 | 0.84 | GPR52 (0.33) | — | |
| SCHEMBL3679783 | 0.80 | — | — | |
| SCHEMBL18033673 | 0.74 | TAAR1 (0.44) | — | |
| SCHEMBL3753516 | 0.72 | — | — | |
| SCHEMBL24595109 | 0.71 | PTGS1 (0.33) | PTGS1PTGS2 | |
| SCHEMBL22032145 | 0.71 | RARB (0.44) | — | |
| SCHEMBL18006789 | 0.69 | CYP2C9 (0.43) | MEN1KMT2AMAOBMAOAPOLB | |
| SCHEMBL25488430 | 0.69 | ESR1 (0.36) | MEN1KMT2ACYP3A4HPGDMAOB | |
| SCHEMBL9133609 | 0.69 | KMT2A (0.55) | MEN1KMT2AHPGDMAOBMAOA | |
| SCHEMBL14424432 | 0.69 | PTGS1 (0.32) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479748-B1 | Tolane derivatives and liquid crystalline medium | MERCK PATENT GMBH (DE) | 2010-03-17 | — | — | EP | disclosed |
| US-7255811-B2 | Tolane derivatives and liquid crystalline medium | MERCK PATENT GMBH (DE) | 2007-08-14 | — | — | US | disclosed |
| US-20040236138-A1 | Tolane derivatives and liquid crystalline medium | MERCK PATENT GMBH (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1479748-A2 | Tolane derivatives and liquid crystalline medium | MERCK PATENT GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236138-A1 | Tolane derivatives and liquid crystalline medium | TLL1, TLL2, TBCD | MEN1 1461/4885KMT2A 4715/4885CYP3A4 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.